BrightLung enables systemic delivery to the alveoli by generating aerosols boasting MMAD’s below three Microns, introducing a new dimension of pulmonary drug administration through the pulmonary system by aerosolization in lieu of the conventional routes of administration hitherto used, resulting in rapid onset and more convenient modes of consumption.

Current inhalation delivery systems face difficulties when required to generate aerosols having MMAD’s (Mass Median Aerodynamic Diameters) below three Microns. As such, they prove suboptimal in treating clinical conditions that necessitate delivery of medications to the Alveolii, constituting the lungs’ deepest area.